Beneficial Effects of Palmitoylethanolamide on Expressive Language, Cognition, and Behaviors in Autism: A Report of Two Cases

Introduction. Autism spectrum disorders are defined by behavioral and language atypias. Growing body of evidence indicates inflammatory mediators may contribute to the condition. Palmitoylethanolamide (PEA) is naturally occurring and has been available as a nonprescription medical food supplement in...

Full description

Saved in:
Bibliographic Details
Main Authors: Nicola Antonucci, Alessandra Cirillo, Dario Siniscalco
Format: Article
Language:English
Published: Wiley 2015-01-01
Series:Case Reports in Psychiatry
Online Access:http://dx.doi.org/10.1155/2015/325061
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832565341113286656
author Nicola Antonucci
Alessandra Cirillo
Dario Siniscalco
author_facet Nicola Antonucci
Alessandra Cirillo
Dario Siniscalco
author_sort Nicola Antonucci
collection DOAJ
description Introduction. Autism spectrum disorders are defined by behavioral and language atypias. Growing body of evidence indicates inflammatory mediators may contribute to the condition. Palmitoylethanolamide (PEA) is naturally occurring and has been available as a nonprescription medical food supplement in Europe since 2008. PEA has been tested in thousands of human subjects without any noted significant side effects. Here we report the first cases of the administration of PEA to two children with autism. Case Presentations. The first 13-year-old male child (Subject 1) presented with a total IgE of 572 IU/mL (nl < 200) and with low mature CD57+ natural killer cell counts (32 cells/µL; nl = 60–300 cells/µL) and with significant eczema and allergic stigmata. Expressive language, as measured by mean length of utterance, and overall autism severity as measured by the Childhood Autism Rating Scale, Second Edition, improved significantly. Atopic symptoms diminished. No side effects were reported. The second male child, age 15 (Subject 2), also displayed noticeable and rapid improvements in cognitive, behaviors, and sociability. Conclusion. Currently, there is no definitive treatment for autism condition. Palmitoylethanolamide could be an effective treatment for autism syndrome. We propose appropriate double-blind clinical trials to further explore palmitoylethanolamide efficacy and safety.
format Article
id doaj-art-f137d32cbc914c66b888cc4b4a501ac6
institution Kabale University
issn 2090-682X
2090-6838
language English
publishDate 2015-01-01
publisher Wiley
record_format Article
series Case Reports in Psychiatry
spelling doaj-art-f137d32cbc914c66b888cc4b4a501ac62025-02-03T01:08:06ZengWileyCase Reports in Psychiatry2090-682X2090-68382015-01-01201510.1155/2015/325061325061Beneficial Effects of Palmitoylethanolamide on Expressive Language, Cognition, and Behaviors in Autism: A Report of Two CasesNicola Antonucci0Alessandra Cirillo1Dario Siniscalco2Biomedical Centre for Autism Research and Treatment, 70126 Bari, ItalyInstitute of Biosciences and Bioresources, National Research Council of Italy, 80128 Naples, ItalyDepartment of Experimental Medicine, Second University of Naples, Via S. Maria di Costantinopoli, 80138 Naples, ItalyIntroduction. Autism spectrum disorders are defined by behavioral and language atypias. Growing body of evidence indicates inflammatory mediators may contribute to the condition. Palmitoylethanolamide (PEA) is naturally occurring and has been available as a nonprescription medical food supplement in Europe since 2008. PEA has been tested in thousands of human subjects without any noted significant side effects. Here we report the first cases of the administration of PEA to two children with autism. Case Presentations. The first 13-year-old male child (Subject 1) presented with a total IgE of 572 IU/mL (nl < 200) and with low mature CD57+ natural killer cell counts (32 cells/µL; nl = 60–300 cells/µL) and with significant eczema and allergic stigmata. Expressive language, as measured by mean length of utterance, and overall autism severity as measured by the Childhood Autism Rating Scale, Second Edition, improved significantly. Atopic symptoms diminished. No side effects were reported. The second male child, age 15 (Subject 2), also displayed noticeable and rapid improvements in cognitive, behaviors, and sociability. Conclusion. Currently, there is no definitive treatment for autism condition. Palmitoylethanolamide could be an effective treatment for autism syndrome. We propose appropriate double-blind clinical trials to further explore palmitoylethanolamide efficacy and safety.http://dx.doi.org/10.1155/2015/325061
spellingShingle Nicola Antonucci
Alessandra Cirillo
Dario Siniscalco
Beneficial Effects of Palmitoylethanolamide on Expressive Language, Cognition, and Behaviors in Autism: A Report of Two Cases
Case Reports in Psychiatry
title Beneficial Effects of Palmitoylethanolamide on Expressive Language, Cognition, and Behaviors in Autism: A Report of Two Cases
title_full Beneficial Effects of Palmitoylethanolamide on Expressive Language, Cognition, and Behaviors in Autism: A Report of Two Cases
title_fullStr Beneficial Effects of Palmitoylethanolamide on Expressive Language, Cognition, and Behaviors in Autism: A Report of Two Cases
title_full_unstemmed Beneficial Effects of Palmitoylethanolamide on Expressive Language, Cognition, and Behaviors in Autism: A Report of Two Cases
title_short Beneficial Effects of Palmitoylethanolamide on Expressive Language, Cognition, and Behaviors in Autism: A Report of Two Cases
title_sort beneficial effects of palmitoylethanolamide on expressive language cognition and behaviors in autism a report of two cases
url http://dx.doi.org/10.1155/2015/325061
work_keys_str_mv AT nicolaantonucci beneficialeffectsofpalmitoylethanolamideonexpressivelanguagecognitionandbehaviorsinautismareportoftwocases
AT alessandracirillo beneficialeffectsofpalmitoylethanolamideonexpressivelanguagecognitionandbehaviorsinautismareportoftwocases
AT dariosiniscalco beneficialeffectsofpalmitoylethanolamideonexpressivelanguagecognitionandbehaviorsinautismareportoftwocases